高原肺动脉高压患者早期药物干预和药物治疗临床研究  

Drug intervention and pharmacotherapy for early high-altitude pulmonary hypertension

作　　者：孔春初[1] KONG Chun-chu(Hunan Provincial People＇s Hospital, Changsha 410002, China)

机构地区：[1]湖南省人民医院,湖南长沙410000

出　　处：《心血管病防治知识（学术版）》2018年第3期11-13,共3页Prevention and Treatment of Cardiovascular Disease

摘　　要：目的研究高原肺动脉高压药物干预治疗早期高原肺动脉高压的临床疗效及安全性。方法将我院临床指导医院山南市人民医院收治的48例患者分为观察组和对照组两组,各组病例数均为24例。予以对照组患者高压氧治疗,在高压氧治疗的基础上予以观察组西地那非联合治疗。对两组患者的临床治疗效果进行评价;治疗前后检测6MWT、Borg评分、SPAP、Sa O2指标值;观察并统计患者相关不良反应的发生率。结果观察组患者临床治疗总有效率为83.34%,对照组为66.67%,两组比较,差异具有统计学意义(P<0.05)。治疗后较治疗前,两组患者平均6MWT指标值均升高(P<0.05),平均Borg评分、SPAP指标值均下降(P<0.05),但在改善幅度上观察组较对照组大(P<0.05)。观察组患者不良反应总发生率为16.67%,对照组为12.5%,两组比较,差异无统计学意义(P>0.05)。结论西地那非治疗早期高原肺动脉高压的临床疗效显著,且不良反应少,安全性好,值得临床推广应用。Objective To investigate the clinical effect and safety of drug intervention in the treatment of early high-altitude pulmonary hypertension. Methods A total of 48 patients who were admitted to Shannan People＇s Hospital guided by our hospital were enrolled and divided into observation group and control group, with 24 patients in each group. The patients in the control group were given hyperbaric oxygen therapy, and those in the observation group were given hyperbaric oxygen therapy combined with sidenafiL The clinical outcome was evaluated for both groups. Six-minute walk test （6MWT） was performed and the Borg score, systolic pulmonary artery pressure （SPAP）, and SaO2 were measured before and after treatment. The incidence rates of adverse reactions were calculated. Results The observation group had a significantly higher overall response rate than the control group （83.34% vs 66.67%, P〈0.05）. After treatment, both groups had a significant increase in mean 6MWT value （/9〈0.05） and significant reductions in mean Borg score and SPAP （P〈0.05）, but the observation group had significantly greater improvements than the control group （P〈O.05）. There was no significant difference in the overall incidence rate of adverse reactions between the observation group and the control group （16.67% vs 12.5%, P〉0.05）. Conclusion Sidenafil has a marked clinical effect in the treatment of early high- altitude pulmonary hypertension, with good safety and few adverse reactions, and therefore, it holds promise for clinical application.

关 键 词：高原肺动脉高压 高压氧 西地那非 

分 类 号：R544.1[医药卫生—心血管疾病]